Min Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Xu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Wen He
Drug clinical Trial GCP Office, Chengdu Fifth People’s Hospital, Chengdu, People’s Republic of China
2 shared publicationsXiaojia Yang
Drug clinical Trial GCP Office, Chengdu Fifth People’s Hospital, Chengdu, People’s Republic of China
2 shared publications- Billy Franks
Haleon BV, Amersfoort, Netherlands
1 shared publication Hengqiu Liu
WuXi Clinical Development Services (Shanghai) Co., Ltd, Shanghai, People’s Republic of China
1 shared publicationJia Lu
1 shared publicationJie Feng
Department of Clinical Pharmacology, Chengdu Fifth People’s Hospital, Chengdu, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-8
Bioequivalence Study of Two Formulations of Ibuprofen Arginine Granules in Healthy Chinese Adult Subjects
Objective: To evaluate the bioequivalence and safety of the test and reference formulations of ibuprofen arginine granules (400 mg) in healthy Chinese adult subjects under fasting and fed conditions. Methods: This was a randomized, open-label, single-center, single-dose, two-treatment, two-sequence, two-period crossover bioequivalence study conducted in separate fasting and fed cohorts. A total of 84 healthy Chinese adults were enrolled, including 34 subjects in the fasting cohort and 50 subjects in the fed cohort. Subjects were randomized to receive either the test formulation followed by the reference formulation or the reverse sequence, with a washout period of at least 2 days between treatments. Plasma ibuprofen concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Pharmacokinetic parameters were calculated using non-compartmental analysis, and bioequivalence was assessed based on geometric mean ratios (GMRs) and corresponding 90% confidence intervals (CIs) for Cmax, AUC0-t, and AUC0-∞. Results: Under fasting conditions, the GMRs (90% CIs) of the test versus reference formulation for AUC0-t, AUC0-∞, and Cmax were 1.0008 (0.9698– 1.0327), 1.0023 (0.9710– 1.0346), and 0.9825 (0.9383– 1.0288), respectively. Under fed conditions, the corresponding values were 0.9916 (0.9755– 1.0081), 0.9776 (0.9432– 1.0133), and 0.9982 (0.9431– 1.0567). All 90% CIs were within the predefined bioequivalence acceptance range of 80.00%-125.00%. No serious adverse events, deaths, or study discontinuations due to adverse events occurred. All treatment-emergent adverse events were mild and resolved without sequelae. Conclusion: The test and reference formulations of ibuprofen arginine granules were bioequivalent under both fasting and fed conditions in healthy Chinese adult subjects. Both formulations were generally safe and well tolerated, with comparable safety profiles.
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-8
Open AccessBioequivalence Study of Two Formulations of Ibuprofen Arginine Granules in Healthy Chinese Adult Subjects
Objective: To evaluate the bioequivalence and safety of the test and reference formulations of ibuprofen arginine granules (400 mg) in healthy Chinese adult subjects under fasting and fed conditions. Methods: This was a randomized, open-label, single-center, single-dose, two-treatment, two-sequence, two-period crossover bioequivalence study conducted in separate fasting and fed cohorts. A total of 84 healthy Chinese adults were enrolled, including 34 subjects in the fasting cohort and 50 subjects in the fed cohort. Subjects were randomized to receive either the test formulation followed by the reference formulation or the reverse sequence, with a washout period of at least 2 days between treatments. Plasma ibuprofen concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Pharmacokinetic parameters were calculated using non-compartmental analysis, and bioequivalence was assessed based on geometric mean ratios (GMRs) and corresponding 90% confidence intervals (CIs) for Cmax, AUC0-t, and AUC0-∞. Results: Under fasting conditions, the GMRs (90% CIs) of the test versus reference formulation for AUC0-t, AUC0-∞, and Cmax were 1.0008 (0.9698– 1.0327), 1.0023 (0.9710– 1.0346), and 0.9825 (0.9383– 1.0288), respectively. Under fed conditions, the corresponding values were 0.9916 (0.9755– 1.0081), 0.9776 (0.9432– 1.0133), and 0.9982 (0.9431– 1.0567). All 90% CIs were within the predefined bioequivalence acceptance range of 80.00%-125.00%. No serious adverse events, deaths, or study discontinuations due to adverse events occurred. All treatment-emergent adverse events were mild and resolved without sequelae. Conclusion: The test and reference formulations of ibuprofen arginine granules were bioequivalent under both fasting and fed conditions in healthy Chinese adult subjects. Both formulations were generally safe and well tolerated, with comparable safety profiles.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects
HBM9378 (SKB378/WIN378) is a novel monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), characterized by an extended half-life and developed to address the unmet medical need for a more durable and convenient biologic therapy for asthma. This first-in-human (FIH) study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378 in healthy subjects, providing essential human data to support further clinical development. This Phase I study utilized a single ascending dose (SAD) design with randomization, double-blinding, and placebo control. Five dose-escalation cohorts were included: 20 mg, 60 mg, 200 mg, 600 mg, and 900 mg. Each cohort comprised ten healthy subjects, of whom eight received HBM9378 at the assigned dose and two received placebo. Safety was evaluated through monitoring of adverse events and laboratory assessments. Pharmacokinetics (PK) were characterized by calculating and comparison of key PK parameters. Immunogenicity was assessed by determining the incidence of anti-drug antibody (ADA) following administration. The safety profiles of the HBM9378 dose groups were comparable to those of the placebo group with respect to treatment-emergent adverse events (TEAEs), and no dose-dependent increase in safety risk was observed. The median Tmax was 4.05–14.1 days and the mean T1/2 was 55.0–65.8 days. HBM9378 exposure (Cmax and AUC) increased dose-proportionally across the 20–900 mg dose range, and the ADA incidence during the study was 5% (2/40). HBM9378 was well-tolerated and exhibited a prolonged half-life in healthy subjects. These results support further investigation of HBM9378 in patients with severe immunological disorders. This trial was registered on ClinicalTrials.gov (NCT05790694) and on the China Center for Drug Evaluation (CDE) platform (CTR20221961).
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessSafety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects
HBM9378 (SKB378/WIN378) is a novel monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), characterized by an extended half-life and developed to address the unmet medical need for a more durable and convenient biologic therapy for asthma. This first-in-human (FIH) study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378 in healthy subjects, providing essential human data to support further clinical development. This Phase I study utilized a single ascending dose (SAD) design with randomization, double-blinding, and placebo control. Five dose-escalation cohorts were included: 20 mg, 60 mg, 200 mg, 600 mg, and 900 mg. Each cohort comprised ten healthy subjects, of whom eight received HBM9378 at the assigned dose and two received placebo. Safety was evaluated through monitoring of adverse events and laboratory assessments. Pharmacokinetics (PK) were characterized by calculating and comparison of key PK parameters. Immunogenicity was assessed by determining the incidence of anti-drug antibody (ADA) following administration. The safety profiles of the HBM9378 dose groups were comparable to those of the placebo group with respect to treatment-emergent adverse events (TEAEs), and no dose-dependent increase in safety risk was observed. The median Tmax was 4.05–14.1 days and the mean T1/2 was 55.0–65.8 days. HBM9378 exposure (Cmax and AUC) increased dose-proportionally across the 20–900 mg dose range, and the ADA incidence during the study was 5% (2/40). HBM9378 was well-tolerated and exhibited a prolonged half-life in healthy subjects. These results support further investigation of HBM9378 in patients with severe immunological disorders. This trial was registered on ClinicalTrials.gov (NCT05790694) and on the China Center for Drug Evaluation (CDE) platform (CTR20221961).